 | Up a level |
2020
Oberbeck, S., Schrader, A., Warner, K., Jungherz, D., Crispatzu, G., von Jan, J., Chmielewski, M., Ianevski, A., Diebner, H. H., Mayer, P., Ados, A. Kondo, Wahnschaffe, L., Braun, T., Mueller, T. A., Wagle, P., Bouska, A., Neumann, T., Puetzer, S., Varghese, L., Pflug, N., Thelen, M., Makalowski, J., Riet, N., Goex, H. J. M., Rappl, G., Altmueller, J., Kotrova, M., Persigehl, T., Hopfinger, G., Hansmann, M. L., Schloesser, H., Stilgenbauer, S., Duerig, J., Mougiakakos, D., Von Bergwelt-Baildon, M., Roeder, I, Hartmann, S., Hallek, M., Moriggl, R., Brueggemann, M., Aittokallio, T., Iqbal, J., Newrzela, S., Abken, H. and Herling, M. (2020). Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling. Blood, 136 (24). S. 2786 - 2803. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
2018
Schrader, A., Crispatzu, G., Oberbeck, S., Mayer, P., Putzer, S., von Jan, J., Vasyutina, E., Warner, K., Weit, N., Pflug, N., Braun, T., Andersson, E. I., Yadav, B., Riabinska, A., Maurer, B., Ferreira, M. S. Ventura, Beier, F., Altmueller, J., Lanasa, M., Herling, C. D., Haferlach, T., Stilgenbauer, S., Hopfinger, G., Peifer, M., Bruemmendorf, T. H., Nuernberg, P., Elenitoba-Johnson, K. S. J., Zha, S., Hallek, M., Moriggl, R., Reinhardt, H. C., Stern, M. -H., Mustjoki, S., Newrzela, S., Frommolt, P. and Herling, M. (2018). Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL. Nat. Commun., 9. LONDON: NATURE PUBLISHING GROUP. ISSN 2041-1723
2017
Al-Sawaf, O., Robrecht, S., Bahlo, J., Fink, A. M., Cramer, P., von Tresckow, J., Maurer, C., Bergmann, M., Seiler, T., Lange, E., Kneba, M., Stilgenbauer, S., Doehner, H., Kiehl, M. G., Jaeger, U., Wendtner, C. M., Fischer, K., Goede, V., Hallek, M., Eichhorst, B. and Hopfinger, G. (2017). Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group. Leukemia, 31 (10). S. 2251 - 2255. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Hoechstetter, M. A., Busch, R., Eichhorst, B., Buehler, A., Winkler, D., Bahlo, J., Eckart, M. J., Vehling-Kaiser, U., Schimke, H., Jaeger, U., Hurtz, H. J., Hopfinger, G., Hartmann, F., Fuss, H., Abenhardt, W., Blau, I., Freier, W., Mueller, L., Goebeler, M., Wendtner, C. M., Fischer, K., Bentz, M., Emmerich, B., Doehner, H., Hallek, M. and Stilgenbauer, S. (2017). A new prognostic model based on clinical, biological and genetic parameters improves prognostication in early stage CLL patients: results of the prospective CLL1 trial of the German CLL study group. Oncol. Res. Treat., 40. S. 25 - 27. BASEL: KARGER. ISSN 2296-5262
Hoechstetter, M. A., Busch, R., Eichhorst, B., Buehler, A., Winkler, D., Eckart, M. J., Vehling-Kaiser, U., Schimke, H., Jaeger, U., Hurtz, H. J., Hopfinger, G., Hartmann, F., Fuss, H., Abenhardt, W., Blau, I., Freier, W., Mueller, L., Goebeler, M., Wendtner, C. M., Bahlo, J., Fischer, K., Bentz, M., Emmerich, B., Doehner, H., Hallek, M. and Stilgenbauer, S. (2017). Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group. Leukemia, 31 (12). S. 2833 - 2838. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
2016
Al-Sawaf, O., Kluth, S., Bahlo, J., Hopfinger, G., Fink, A. M., Cramer, P., Maurer, C., Bergmann, M., Dreyling, M., Lange, E., Kneba, M., Stilgenbauer, S., Kiehl, M. G., Jaeger, U., Wendtner, C. M., Fischer, K., Hallek, M. and Eichhorst, B. (2016). Impact of gender on outcome after chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) or bendamustin plus R (BR) in CLL patients: a pooled analysis of the German CLL Study Group (GCLLSG). Oncol. Res. Treat., 39. S. 212 - 214. BASEL: KARGER. ISSN 2296-5262
2015
Hopfinger, G. and Herling, M. (2015). T-cell prolymphocytic leukemia - an update. Oncol. Res. Treat., 38. S. 257 - 258. BASEL: KARGER. ISSN 2296-5262
2010
Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A. M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Gruenhagen, U., Bergmann, M., Catalano, J., Zinzani, P. L., Caligaris-Cappio, F., Seymour, J. F., Berrebi, A., Jaeger, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C. M., Eichhorst, B. F., Staib, P., Buehler, A., Winkler, D., Zenz, T., Boettcher, S., Ritgen, M., Mendila, M., Kneba, M., Doehner, H. and Stilgenbauer, S. (2010). Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 376 (9747). S. 1164 - 1175. NEW YORK: ELSEVIER SCIENCE INC. ISSN 0140-6736
Shehata, M., Demirtas, D., Schnabl, S., Hilgarth, M., Hubmann, R., Fonatsch, C., Schwarzinger, I., Hopfinger, G., Eigenberger, K., Heintel, D., Porpaczy, E., Vanura, K., Hauswirth, A., Schwarzmeier, J. D., Gaiger, A., Stilgenbauer, S., Hallek, M., Bilban, M. and Jaeger, U. (2010). Sequential gene expression profiling during treatment for identification of predictive markers and novel therapeutic targets in chronic lymphocytic leukemia. Leukemia, 24 (12). S. 2122 - 2128. LONDON: NATURE PUBLISHING GROUP. ISSN 0887-6924